Earnshaw J J, Gregson R H, Makin G S, Hopkinson B R
Br J Surg. 1987 Jun;74(6):504-7. doi: 10.1002/bjs.1800740629.
Thirty-two patients with acute and subacute limb-threatening peripheral arterial ischaemia were treated with low dose intra-arterial streptokinase infusions. The mean duration of infusion was 38 h. Six patients developed pericatheter thrombosis and two had distal embolization of fragments of thrombus but in all cases these responded to repositioning the catheter and continuing the infusion. Five patients developed groin haematomata and in three of these there was evidence of a systemic fibrinolytic effect from the streptokinase with plasma fibrinogen reduced below 1 g/l. The most serious complication was perforation of the popliteal and tibial arteries which occurred on two occasions and required cessation of the infusion. Twenty-two patients (69 per cent) achieved limb salvage, eight (25 per cent) suffered a major amputation and two (6 per cent) died. The outcome was not related to the site, nature or duration of the arterial occlusion but patients with loss of sensation or paralysis of the affected limb were significantly less likely to obtain limb salvage (P = 0.001). For occlusions greater than 30 cm in length a new technique was used where the thrombus was lysed from distal to proximal in short lengths by gradual catheter withdrawal. This was successful in five out of six cases. Low dose intra-arterial streptokinase has been confirmed as an effective, relatively safe method of treatment in recent arterial ischaemia and can be recommended in situations where the results of surgery may not be favourable. In particular, patients with arterial thromboses and no distal run-off, distal and late arterial emboli, thrombosed popliteal aneurysms and patients after a failed embolectomy, have all been shown to respond to thrombolytic therapy with intra-arterial streptokinase.
32例患有急性和亚急性肢体威胁性外周动脉缺血的患者接受了低剂量动脉内链激酶输注治疗。平均输注持续时间为38小时。6例患者发生导管周围血栓形成,2例出现血栓碎片远端栓塞,但所有这些情况均通过重新放置导管和继续输注得到缓解。5例患者出现腹股沟血肿,其中3例有链激酶引起全身纤维蛋白溶解作用的证据,血浆纤维蛋白原降至1g/L以下。最严重的并发症是腘动脉和胫动脉穿孔,发生了2次,需要停止输注。22例患者(69%)肢体得以挽救,8例(25%)接受了大截肢,2例(6%)死亡。结果与动脉闭塞的部位、性质或持续时间无关,但患肢感觉丧失或瘫痪的患者肢体得以挽救的可能性显著降低(P = 0.001)。对于长度大于30cm的闭塞,采用了一种新技术,即通过逐渐回撤导管,从远端到近端短段溶解血栓。6例中有5例成功。低剂量动脉内链激酶已被确认为近期动脉缺血的一种有效且相对安全的治疗方法,在手术结果可能不理想的情况下可以推荐使用。特别是,动脉血栓形成且无远端血流、远端和晚期动脉栓塞、腘动脉瘤血栓形成以及取栓术失败后的患者,均已显示对动脉内链激酶溶栓治疗有反应。